Publications

• Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).

  (Gordon KB, Warren RB, Gottlieb AB, Blauvelt A, Thaçi D, Leonardi C, Poulin Y, Boehnlein M, Brock F, Ecoffet C, Reich K.) Br J Dermatol. 2021 Apr;184(4):652-662 PMID: 32652544 SCOPUS ID: 2-s2.0-85090447727 07/12/2020

• Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.

  (Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Siegel M, Stoff B, Strober B, Wu JJ, Hariharan V, Menter A.) J Am Acad Dermatol. 2021 Feb;84(2):432-470 PMID: 32738429 08/02/2020

• Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

  (Gordon KB, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, White K, Cioffi C, Blauvelt A.) The Lancet. 6 February 2021;397(10273):475-486 SCOPUS ID: 2-s2.0-85100381587 02/06/2021

• Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.

  (Callis Duffin K, Mason MA, Gordon K, Harrison RW, Crabtree MM, Guana A, Germino R, Lebwohl M.) Dermatology. 2021;237(1):46-55 PMID: 31962340 PMCID: PMC7845438 01/22/2020

• Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.

  (Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB.) JAMA Dermatol. 2020 12 01;156(12):1344-1353 PMID: 33052382 PMCID: PMC7557488 SCOPUS ID: 2-s2.0-85094184750 10/15/2020

• Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.

  (Reich K, Armstrong AW, Foley P, Song M, Miller M, Shen YK, You Y, Han C, Gordon KB.) Am J Clin Dermatol. 2020 Dec;21(6):881-890 PMID: 32910434 SCOPUS ID: 2-s2.0-85090788734 09/11/2020

• Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.

  (Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P.) J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2830-2838 PMID: 32320088 PMCID: PMC7818271 SCOPUS ID: 2-s2.0-85087425049 04/23/2020

• Cutaneous Manifestations of Chronic Liver Disease.

  (Patel AD, Katz K, Gordon KB.) Clin Liver Dis. 2020 08;24(3):351-360 PMID: 32620276 SCOPUS ID: 2-s2.0-85085606303 07/06/2020

• Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.

  (Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA.) J Am Acad Dermatol. 2020 Jun;82(6):1445-1486 PMID: 32119894 SCOPUS ID: 2-s2.0-85083507157 03/03/2020

• A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.

  (Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J, IXORA-R Study Group.) Br J Dermatol. 2020 06;182(6):1348-1358 PMID: 31887225 PMCID: PMC7317420 SCOPUS ID: 2-s2.0-85078277463 12/31/2019

• Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.

  (Reich K, Griffiths CEM, Gordon KB, Papp KA, Song M, Randazzo B, Li S, Shen YK, Han C, Kimball AB, Armstrong AW, Foley P, Blauvelt A.) J Am Acad Dermatol. 2020 Apr;82(4):936-945 PMID: 31809827 SCOPUS ID: 2-s2.0-85078983517 12/07/2019

• Comparative Effectiveness Studies for Psoriasis-The Methods Matter.

  (Strober B, Gordon KB.) JAMA Dermatol. 2020 03 01;156(3):253-255 PMID: 32022830 SCOPUS ID: 2-s2.0-85079151739 02/06/2020